These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 7624286

  • 1. A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models.
    Mehlhorn H, Dankert W, Hartman PG, Then RL.
    Parasitol Res; 1995; 81(4):296-301. PubMed ID: 7624286
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii.
    Chang HR, Arsenijevic D, Comte R, Polak A, Then RL, Pechère JC.
    Antimicrob Agents Chemother; 1994 Aug; 38(8):1803-7. PubMed ID: 7986011
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia.
    Walzer PD, Kim CK, Foy JM, Linke MJ, Cushion MT.
    Antimicrob Agents Chemother; 1988 Jan; 32(1):96-103. PubMed ID: 3258144
    [Abstract] [Full Text] [Related]

  • 9. Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii.
    Kovacs JA, Allegra CJ, Chabner BA, Swan JC, Drake J, Lunde M, Parrillo JE, Masur H.
    J Infect Dis; 1987 May; 155(5):1027-32. PubMed ID: 2951446
    [Abstract] [Full Text] [Related]

  • 10. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
    Bucher HC, Griffith L, Guyatt GH, Opravil M.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jun 01; 15(2):104-14. PubMed ID: 9241108
    [Abstract] [Full Text] [Related]

  • 11. In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.
    Romand S, Bryskier A, Moutot M, Derouin F.
    J Antimicrob Chemother; 1995 Jun 01; 35(6):821-32. PubMed ID: 7559193
    [Abstract] [Full Text] [Related]

  • 12. Relative potency of 10 drugs with anti-Pneumocystis carinii activity in an animal model.
    Hughes WT, Killmar JT, Oz HS.
    J Infect Dis; 1994 Oct 01; 170(4):906-11. PubMed ID: 7930735
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii.
    Gross U, Pohl F.
    Curr Top Microbiol Immunol; 1996 Oct 01; 219():235-45. PubMed ID: 8791704
    [No Abstract] [Full Text] [Related]

  • 18. A clinical-parasitological monotherapy cure in the treatment of experimental infection by a highly virulent strain of Toxoplasma gondii.
    de Diego JA, Penin P, Arribas JR, Vázquez E, Vázquez JJ.
    Folia Microbiol (Praha); 1996 Oct 01; 41(6):513-6. PubMed ID: 9131805
    [Abstract] [Full Text] [Related]

  • 19. Lack of activity of artemether for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii infections in rat.
    Brun-Pascaud M, Chau F, Derouin F, Girard PM.
    Parasite; 1996 Jun 01; 3(2):187-9. PubMed ID: 8758556
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.